1. Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
- Author
-
Johnson PJ, Pinato DJ, Kalyuzhnyy A, and Toyoda H
- Subjects
- Humans, Liver Cirrhosis, Phenylurea Compounds, Retrospective Studies, Sorafenib, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular therapy, Liver Neoplasms pathology, Liver Neoplasms therapy
- Abstract
Competing Interests: David J. PinatoHonoraria: Roche/Genentech, Bristol Myers Squibb, Da Volterra, Avamune, MurslaConsulting or Advisory Role: EISAI, Mina Therapeutics, Roche, H3 Biomedicine, Da Volterra, AstraZeneca, IpsenSpeakers' Bureau: Bayer, ViiV Healthcare, Falk Pharma, RocheResearch Funding: MSD Oncology (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst)Travel, Accommodations, Expenses: Bristol Myers Squibb, Bayer, MSD OncologyOther Relationship: Wiley Hidenori ToyodaHonoraria: AbbVie, Bayer Yakuhin, Gilead Sciences, MSD K.K, Janssen, Eisai, Chugai Pharma, Otsuka, TerumoSpeakers' Bureau: AbbVie, Gilead Sciences, MSD, Bayer, EisaiNo other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF